66658-57-9

Basic information

• Product Name: 5-BROMOMETHYL-2-CHLOROBENZOIC ACID
• Synonyms: 5-BROMOMETHYL-2-CHLOROBENZOIC ACID
• CAS NO: 66658-57-9
• Molecular Formula: C₈H₆BrClO₂
• Molecular Weight: 249.49
• Mol File: 66658-57-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-BROMOMETHYL-2-CHLOROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMOMETHYL-2-CHLOROBENZOIC ACID(66658-57-9)
• EPA Substance Registry System: 5-BROMOMETHYL-2-CHLOROBENZOIC ACID(66658-57-9)

Safety Data

• Hazardous Substances Data: 66658-57-9(Hazardous Substances Data)

Upstream product

• 6342-60-5 2-chloro-5-methyl-benzoic acid 
• 16220-99-8 5-bromomethyl-2-chloro-benzoic acid methyl ester 

Downstream Products

• 1187239-03-7 C₂₈H₂₇BrClNO₅S 
• 301672-94-6 4-[[4-chloro-3-[[(tricyclo[3.3.1.1^3,7]dec-1-ylmethyl)amino]carbonyl]phenyl]methylene]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 
• 301672-56-0 2-Chloro-5-[(5,6-dihydro-1(4H)-pyrimidinyl)methyl]-N-(tricyclo[3.3.1.13.7]dec-1-ylmethyl)-benzamide 
• 301672-79-7 4-[[4-Chloro-3-[[(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)amino]carbonyl]-phenyl]methyl]-1-piperazinecarboxylic acid, 1,1-dimethylethyl ester 
• 1179337-94-0 2-Chloro-5-(2-hydroxyethyl)benzaldehyde 
• 66658-58-0 2-chloro-5-(cyanomethyl)benzoic acid 
• 1179337-93-9 2-(4-chloro-3-(hydroxymethyl)phenyl)ethanol 
• 1179337-92-8 5-(carboxymethyl)-2-chlorobenzoic acid 
• 301672-78-6 5-(bromomethyl)-2-chloro-N-(2-tricyclo[3.3.1.13.7]dec-1-ylethyl)-benzamide 
• 301672-76-4 5-bromomethyl-2-chloro-N-(tricyclo[3.3.1.1^3,7]dec-1-ylmethyl)-benzamide 

Relevant articles and documents

BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to benzamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Design, synthesis and identification of novel colchicine-derived immunosuppressant

Synthesis and biological evaluation of various colchicine analogues through the mixed-lymphocyte reaction (MLR), lymphoproliferation, and inhibitory effects on the inflammatory genes are described. In addition, a new series of immunosuppressive agents developed on the structural basis of colchicine, as well as their structure-activity relationships is reported. The most potent analogue 20a exhibited an excellent immunosuppressive activity on in vivo skin-allograft model, which is comparable to that of cyclosporin A.

Adamantane derivatives

The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CHs